A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)
This phase II study of eribulin for patients with BRAF V600E mutant mCRC did not meet the primary endpoint. Although BM2 on gene expression analysis of BM subtype may be a predictive marker of eribulin efficacy, further studies are required to validate this hypothesis.
Authors
- T. Nishina
- Nozomu Fuse (ORCID: https://orcid.org/0000-0002-7123-0167)
- Gaurav Sharma (ORCID: https://orcid.org/0000-0002-4326-5231)
- Yu Sunakawa (ORCID: https://orcid.org/0000-0002-0163-7543)
- Hiroko Ichiki (ORCID: https://orcid.org/0000-0002-3197-9050)
- Yoshiaki Nakamura (ORCID: https://orcid.org/0000-0002-5241-6855)
- Noriko Fujishiro
- Atsushi Ohtsu (ORCID: https://orcid.org/0000-0003-1329-0628)
- Hideaki Ono (ORCID: https://orcid.org/0000-0001-9615-0553)
- Daisuke Kotani (ORCID: https://orcid.org/0000-0002-4196-555X)
- Toshiki Masuishi (ORCID: https://orcid.org/0000-0002-7521-1596)
- Hideaki Bando (ORCID: https://orcid.org/0000-0001-5041-2765)
- Akihito Sato (ORCID: https://orcid.org/0000-0002-3109-4498)
- Yoshito Komatsu (ORCID: https://orcid.org/0000-0002-1570-6802)
- Taito Esaki (ORCID: https://orcid.org/0000-0002-9169-8453)
- Masashi Wakabayashi (ORCID: https://orcid.org/0009-0001-6368-5671)
- Y. Sakamoto
- Taroh Satoh (ORCID: https://orcid.org/0000-0002-4615-2638)
- Naomi Kuramoto
- Shogo Nomura (ORCID: https://orcid.org/0000-0001-8734-6984)
- Eiji Shinozaki (ORCID: https://orcid.org/0000-0002-7448-5894)
- Eric T. Schultz (ORCID: https://orcid.org/0000-0003-4086-7883)
- Hiroya Taniguchi (ORCID: https://orcid.org/0000-0003-1407-6682)
- Miki Izumi
- T. Yoshino
- Stan Skrzypczak
- Keiko Takahashi (ORCID: https://orcid.org/0009-0000-3348-3860)
- Carl Kingsford
- Nami Hirano
Institutions
- St. Marianna University School of Medicine (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- ID Genomics (United States) (US)
- Aichi Cancer Center (JP)
- Shikoku Cancer Center (JP)
- Hokkaido University Hospital (JP)
- National Cancer Center Hospital East (JP)
- Osaka University Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105839
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Jazz Pharmaceuticals
- Nihon Medi-Physics
- Kowa Company
- Boehringer Ingelheim Japan
- Azərbaycan Milli Elmlər Akademiyası
- Seagen
- Natera
- Eisai
- Astellas Pharma
- Pfizer Japan
- Chugai Pharmaceutical
- Ignyta
- Daiichi Sankyo Europe